FDA Approves First Personalized Cell Therapy for Multiple Myeloma

TThe Food and Drug Administration approved the first personalized cell therapy to treat patients with advanced multiple myeloma on Friday. It will be marketed under the Abecma brand by its manufacturers, Bristol Myers Squibb and Bluebird Bio.

Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cell that helps fight infection. In people with multiple myeloma, malignant plasma cells accumulate in the bone marrow, where they crowd out healthy blood cells, causing tumors, kidney damage, bone destruction, and impaired immune function.

Unlock this item by subscribing to STAT + and enjoy your first 30 days for free!


Source link